This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Modlich, O. Articles by Bojar, H. Search for Related Content PubMed PubMed Citation Articles by Modlich, O. Articles by Bojar, H.

Immediate Gene Expression Changes After the First Course of Neoadjuvant Chemotherapy in Patients with Primary Breast Cancer Disease

¹ Institute of Chemical Oncology, University of Düsseldorf, Düsseldorf; ² Bayer Healthcare AG, Diagnostic Research Germany, Leverkusen; and ³ Interdisciplinary Breast Center IBC, City Hospital Düsseldorf, Düsseldorf, Germany

ABSTRACT

Purpose: Our goal was to identify genes undergoing expressional changes shortly after the beginning of neoadjuvant chemotherapy for primary breast cancer.

Experimental Design: The biopsies were taken from patients with primary breast cancer prior to any treatment and 24 hours after the beginning of the neoadjuvant chemotherapy. Expression analyses from matched pair samples representing 25 patients were carried out with Clontech filter arrays. A subcohort of those 25 paired samples were additionally analyzed with the Affymetrix GeneChip platform. All of the transcripts from both platforms were queried for expressional changes.

Results: Performing hierarchical cluster analysis, we clustered pre- and posttreatment samples from individual patients more closely to each other than the samples taken from different patients. This reflects the rather low number of transcripts responding directly to the drugs used. Although transcriptional drug response occurring during therapy differed between individual patients, two genes (p21^WAF1/CIP1 and MIC-1) were up-regulated in posttreatment samples. This could be validated by semiquantitative and real-time reverse transcription-PCR. Partial least- discriminant analysis based on approximately 25 genes independently identified by either Clontech or Affymetrix platforms could clearly discriminate pre- and posttreatment samples. However, correlation of certain gene expression levels as well as of differential patterns and clusters as determined by a different platform was not always satisfying.

Conclusions: This study has demonstrated the potential of monitoring posttreatment changes in gene expression as a measure of the pharmacodynamics of drugs. As a clinical laboratory model, it can be useful to identify patients with sensitive and reactive tumors and to help for optimized choice for sequential therapy and obviously improve relapse- free and overall survival.

This article has been cited by other articles:

				S. Puhalla, E. Mrozek, D. Young, S. Ottman, A. McVey, K. Kendra, N. J. Merriman, M. Knapp, T. Patel, M. E. Thompson, et al. Randomized Phase II Adjuvant Trial of Dose-Dense Docetaxel Before or After Doxorubicin Plus Cyclophosphamide in Axillary Node-Positive Breast Cancer J. Clin. Oncol., April 1, 2008; 26(10): 1691 - 1697. [Abstract] [Full Text] [PDF]

				C.-Y. Huang, T. M. Beer, C. S. Higano, L. D. True, R. Vessella, P. H. Lange, M. Garzotto, and P. S. Nelson Molecular Alterations in Prostate Carcinomas that Associate with In vivo Exposure to Chemotherapy: Identification of a Cytoprotective Mechanism Involving Growth Differentiation Factor 15 Clin. Cancer Res., October 1, 2007; 13(19): 5825 - 5833. [Abstract] [Full Text] [PDF]

				S. Calza, W. Raffelsberger, A. Ploner, J. Sahel, T. Leveillard, and Y. Pawitan Filtering genes to improve sensitivity in oligonucleotide microarray data analysis Nucleic Acids Res., August 28, 2007; (2007) gkm537v2. [Abstract] [Full Text] [PDF]

				S. K Gruvberger-Saal, H. E Cunliffe, K. M Carr, and I. A Hedenfalk Microarrays in breast cancer research and clinical practice - the future lies ahead Endocr. Relat. Cancer, December 1, 2006; 13(4): 1017 - 1031. [Abstract] [Full Text] [PDF]

				J. M. Martinez, T. Sali, R. Okazaki, C. Anna, M. Hollingshead, C. Hose, A. Monks, N. J. Walker, S. J. Baek, and T. E. Eling Drug-Induced Expression of Nonsteroidal Anti-Inflammatory Drug-Activated Gene/Macrophage Inhibitory Cytokine-1/Prostate-Derived Factor, a Putative Tumor Suppressor, Inhibits Tumor Growth J. Pharmacol. Exp. Ther., August 1, 2006; 318(2): 899 - 906. [Abstract] [Full Text] [PDF]

				A. R. Bauskin, D. A. Brown, T. Kuffner, H. Johnen, X. W. Luo, M. Hunter, and S. N. Breit Role of macrophage inhibitory cytokine-1 in tumorigenesis and diagnosis of cancer. Cancer Res., May 15, 2006; 66(10): 4983 - 4986. [Abstract] [Full Text] [PDF]

				W. Wollmann, M. L. Goodman, P. Bhat-Nakshatri, H. Kishimoto, R. J. Goulet Jr, S. Mehrotra, A. Morimiya, S. Badve, and H. Nakshatri The macrophage inhibitory cytokine integrates AKT/PKB and MAP kinase signaling pathways in breast cancer cells Carcinogenesis, May 1, 2005; 26(5): 900 - 907. [Abstract] [Full Text] [PDF]

				J. Geisler and P. E. Lonning Aromatase Inhibition: Translation into a Successful Therapeutic Approach Clin. Cancer Res., April 15, 2005; 11(8): 2809 - 2821. [Abstract] [Full Text] [PDF]